Omnicare, Inc. (NYSE:OCR)

CAPS Rating: 4 out of 5

A geriatric pharmaceutical services company, which provides pharmaceuticals and related ancillary pharmacy services to long-term healthcare institutions. Operates in two business segments: Pharmacy Services and Contract Research Organization Services.

Results 1 - 20 of 31 : 1 2 Next »

Recs

1
Member Avatar TMFPennyWise (< 20) Submitted: 8/26/2013 3:16:41 PM : Outperform Start Price: $30.66 OCR Score: +83.32

What they say about buying stock in companies in your own locale that you know and can watch carefully has some validity with me. I have watched Omnicare for the past couple of years as it struggled to settle and recover from some unfair practices and other court issues, then clean up management and restructure, and finally I think it has emerged as a strong competitor in the pharmaceutical distribution sector (specializing in care facilities). In fact, I just read that they picked up the Kindred Healthcare Inc. $29 million contract from Pharmerica so I think they may be on a roll. This company has room to run with the prospect of a growing elder population and I think it's a buy.

Recs

2
Member Avatar forexnutca (85.29) Submitted: 2/17/2011 3:02:26 PM : Outperform Start Price: $23.53 OCR Score: +135.21

A stock that has been hurt by health care reform and continued cuts by patient care facilities. In particular cost cuts in Medicare Part D. All that being said, this stock has been trading below book value and has continued to throw off huge growing cash flows (trading around 10x cash flow at present). What this company will lose in reduced patient care costs, it will gain in patient volumes over the years. There is some serious future potential for Omnicare. Recent management change is a plus and the company has recently been turning lemons into lemonade (it also services these patient care facilities as far as compliance relations.) Where's the Moat? Omnicare is the largest pharma service company in NA with a huge logistics and delivery operation. They offer compliance consulting, CRO services (for all stages of drug testing), and contract based pharmacy services. They also have a wide database of patient data. In these heavily regulated environments, this company is a necessity to most patient care facilities and will continue to prosper in a sector that has potential for huge growth.

Recs

0
Member Avatar AnchorageAK (< 20) Submitted: 11/28/2010 5:56:09 PM : Outperform Start Price: $21.93 OCR Score: +145.81

Pharmaceutical management for healthcare service facilities. All these aging babyboomers provide a massive growing demand base.

Recs

0
Member Avatar dougsowder (45.76) Submitted: 6/2/2010 12:43:39 PM : Outperform Start Price: $23.74 OCR Score: +106.31

Will benefit greatly from the Health care plan, plus undervalued.

Recs

0
Member Avatar musclemilk13 (99.45) Submitted: 4/12/2010 3:41:17 PM : Outperform Start Price: $28.98 OCR Score: +69.56

4/12 screen #2: percentile and CS

Recs

0
Member Avatar gnaltieri (< 20) Submitted: 8/5/2009 9:50:08 AM : Outperform Start Price: $22.66 OCR Score: +101.72

Being a sizable stockholder for 13 years I am certainly in hopes that it finally catches up with my cost (34.50) 13 years ago. Come on everybody buy some.

Recs

1
Member Avatar RXDOC73 (99.36) Submitted: 8/3/2009 12:36:37 PM : Outperform Start Price: $22.56 OCR Score: +104.01

Good balance sheet and also good acquisition target.

Recs

0
Member Avatar agentscarn (31.98) Submitted: 3/11/2009 4:39:20 PM : Outperform Start Price: $22.88 OCR Score: +17.05

net income growth by 37%

Recs

0
Member Avatar skyprince60 (37.26) Submitted: 11/13/2008 2:37:38 PM : Outperform Start Price: $23.11 OCR Score: +62.29

Well run company in a growing space that is on sale at incredible low price.

Recs

0
Member Avatar GoyangDangdut (< 20) Submitted: 6/25/2008 4:42:46 AM : Outperform Start Price: $23.46 OCR Score: +137.38

OCR will anooune its earning that historical has gowth in relative strength

Recs

1
Member Avatar grammatoncleric (< 20) Submitted: 3/12/2008 1:10:14 PM : Underperform Start Price: $16.19 OCR Score: -271.46

health care

Recs

3
Member Avatar doggetla (52.59) Submitted: 11/7/2007 7:09:33 AM : Outperform Start Price: $25.46 OCR Score: +131.95

OCR will be one of the surprising 3 star stocks. current very undervalued IV of 54.00

pay a small dividend for your wait.

oh!! by the way america is getting OLDER!!!!!

old age more drugs, keep your cost down buy generic, equals OCR

Recs

0
Member Avatar DeepSouthValue (< 20) Submitted: 9/7/2007 11:01:09 AM : Outperform Start Price: $29.33 OCR Score: +90.15

love those monopolies

Recs

0
Member Avatar holopoj (39.84) Submitted: 8/27/2007 12:19:44 PM : Outperform Start Price: $31.29 OCR Score: +76.69

Looks way undervalued compared to historical P/E

Recs

0
Member Avatar wgscogen (33.71) Submitted: 5/12/2007 3:25:45 PM : Outperform Start Price: $33.68 OCR Score: +63.59

market over-reacting to bad news. OCR will return to form and expect a nice bounce

Recs

0
Member Avatar gavinsblog (63.29) Submitted: 4/30/2007 1:08:03 PM : Outperform Start Price: $31.90 OCR Score: +74.05

Unwarranted fall, IV.

Recs

0
Member Avatar pomskua (70.38) Submitted: 4/27/2007 11:17:53 AM : Outperform Start Price: $33.96 OCR Score: +60.20

Entering during what I think is an overreaction to poor Q1 results. This leading company is in a field where aging boomers will be a driving factor for decades.

Recs

1
Member Avatar kleiv (76.63) Submitted: 3/5/2007 2:31:27 PM : Outperform Start Price: $36.81 OCR Score: +32.35

A near monopoly in institutional pharmecueticals. Top line growth along with margin improvement over the next 2 years. Problems of late are temporary, have nothing to do with long term viability of the business.

Recs

0
Member Avatar cddg (< 20) Submitted: 1/24/2007 9:18:02 AM : Outperform Start Price: $36.50 OCR Score: +38.81

think guidence could come in better than the street expects on PDP rates and restructuring

Recs

0
Member Avatar fmurphyiii (70.36) Submitted: 12/28/2006 10:48:11 AM : Outperform Start Price: $36.85 OCR Score: +35.98

Undervalued because of rough stretch last year. Has everything in place to excel. Watch for possible negative regulatory environment and evidence of further customer retention issues.

Results 1 - 20 of 31 : 1 2 Next »

Featured Broker Partners


Advertisement